Tags: Cancer | blood | cancer | Pomalyst | multiple | myeloma | drug

New Lifesaving Blood Cancer Drug OKd

Thursday, 07 Mar 2013 09:27 AM

 


Pomalyst (pomalidomide) has been approved by the FDA to treat cases of multiple myeloma that have not responded to other therapies.

The disease, a form of blood cancer, affects some 21,700 Americans annually and nearly 10,700 die from it each year, the agency said Friday in a news release.

Pomalyst is designed to spur the immune system to destroy and inhibit cancer cells, the FDA said. The drug's safety and effectiveness were evaluated in a clinical study of 221 people with advanced multiple myeloma.

Obamacare
: Massive New Rules Revealed for 2013

The drug's label will contain a boxed warning that it shouldn't be used by pregnant women since it can cause life-threatening birth defects and blood clots, the FDA said.

More common side effects could include a drop in infection-fighting white blood cells, fatigue, weakness, other blood disorders, back pain and fever.

The drug is marketed by Celgene, based in Summit, N.J.

© HealthDay

1Like our page
2Share
 

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved